JGHG yields 72.46% · JNJ yields 2.13%● Live data
📍 JGHG pulled ahead of the other in Year 1
Combined, JGHG + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JGHG + JNJ for your $10,000?
Jinzisheng Holding Group, a development stage company, develops and sells enterprise mobile marketing applications solutions, kiosk hardware, and software products. Its solutions include m2Meet, a community networking software solution; m2Bank, a financial transactions system that facilitates bill payments, money transfers, and account management; and m2Market, a mobile marketing solution that is used to deliver marketing materials to mobile phones. The company also offers m2Ticket, a mobile ticketing sales engine, which manages the sale and delivery of tickets through mobile phones for the transportation and entertainment industry; m2Kiosk, a line of standard and custom kiosks hardware and software that integrates with mobile phone applications in the marketing, financial, and ticketing industries; and m2Workflow, a customer relations management solution on mobile phones for service industries. In addition, it develops and licenses portal software products that enable customers to operate their own online social networking portal without requiring any technical programming or Website design skills, as well as provides custom software programming services to customers who license its products. Further, the company specializes in data and voice telecommunications technologies. Jinzisheng Holding Group was founded in 2004 and is based in Toronto, Canada.
Full JGHG Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.